# EDGAR Filing Document

**Accession Number:** 0001347242
**File Stem:** 0001753926-25-001003
**Filing Date:** 2025-6
**Character Count:** 23919
**Document Hash:** 09463e437156f192812ac732935af66e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001753926-25-001003.hdr.sgml**: 20250625

**ACCESSION NUMBER**: 0001753926-25-001003

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250625

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250625

**DATE AS OF CHANGE**: 20250625

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LIPELLA PHARMACEUTICALS INC.
- **CENTRAL INDEX KEY:** 0001347242
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41575
- **FILM NUMBER:** 251073322

**BUSINESS ADDRESS:**
- **STREET 1:** 400 N LEXINGTON ST
- **STREET 2:** STE LL103
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15208
- **BUSINESS PHONE:** 412-901-0315

**MAIL ADDRESS:**
- **STREET 1:** 400 N LEXINGTON ST
- **STREET 2:** STE LL103
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15208

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LIPELLA PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20051219

?xml version='1.0' encoding='ASCII'?

 **UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 25, 2025**

**Lipella Pharmaceuticals Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **005-93847** | **20-2388040** |
| (State or other jurisdiction <br> of incorporation) | (Commission File Number) | (IRS Employer <br> Identification No.) |

---

---

| | |
|:---|:---|
| **7800 Susquehanna St., Suite 505**<br> **Pittsburgh, PA** | **15208** |
| (Address of registrant's principal executive office) | (Zip code) |

---

Registrant's telephone number, including area code: **(412) 894-1853**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| - | - | - |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure**

Reference is made to the disclosure in Item 8.01 of this Current Report on Form 8-K (this "Form 8-K"), which disclosure is incorporated herein by reference. The Stockholder Letter and the Press Release (each as defined below) are filed herewith as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

The information contained in this Form 8-K under Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, shall be deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this Form 8-K in such filing. The information set forth in this Item 7.01 of this Form 8-K and Exhibits 99.1 and 99.2 attached hereto shall not be deemed an admission as to the materiality of any information in this Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

**Item 8.01 Other Events.**

On June 25, 2025, Lipella Pharmaceuticals Inc., a Delaware corporation (the "Company", "we", "us" or "our"), released a letter (the "Stockholder Letter") from Jonathan Kaufman, the Company's Chief Executive Officer, to the Company's stockholders regarding the Company's recent delisting from the Nasdaq Capital Market and its subsequent outlook, including its plans to relist on a national exchange. A copy of the Stockholder Letter is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The Company's press release announcing the Stockholder Letter on June 25, 2025 (the "Press Release") is attached as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference.

*Cautionary Statement Regarding Forward-Looking Statements*

This Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities, or future events or conditions, including, without limitation, those related to the anticipated developments of the Company's product candidates developments and the Company's plans to relist its common stock, which can be identified by terminology such as "may," "will," "expects," "anticipates," "aims," "potential," "future," "intends," "plans," "believes," "estimates," "continue," "likely to" and other similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are not historical facts and are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by its management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict, many of which are beyond the Company's control, including, without limitation, risks related to the Company's product candidates and ability to relist its common stock, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the SEC. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements. Any forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this Form 8-K, except as required by applicable law.

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Stockholder Letter, dated June 25, 2025](g084855_ex99-1.htm) |
| 99.2 | [Press Release, dated June 25, 2025](g084855_ex99-2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 25, 2025 | **Lipella Pharmaceuticals Inc.** | **Lipella Pharmaceuticals Inc.** |
|  | By:  | /s/ Jonathan Kaufman |
|  |  | Name: Jonathan Kaufman<br> Title: Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**LIPELLA PHARMACEUTICALS INC.**

**LETTER FROM THE CEO**

Dear Fellow Stockholders:

Over the past few days, I have received many calls, texts, and emails asking questions about our status. In a genuine effort to keep stockholders up to date, I have reproduced the majority of questions received, along with responses so that all stockholders can understand where the Company currently stands and its current prospects and plans.

**1. Why was Lipella delisted from Nasdaq?**

Nasdaq determined that certain private placement transactions completed between December 2024 and March 2025 did not comply with Listing Rules 5100 (public interest concern), 5635 (stockholder approval), and 5640 (voting rights). Specifically, Nasdaq cited the issuance of Series C voting convertible preferred stock and warrants to the Company's placement agent and advisor as partial compensation for services rendered during these offerings ultimately requiring stockholder approval as the reason for such determination. Despite our prompt and diligent efforts to address the staff's concerns, including steps to quickly obtain stockholder approval, the Nasdaq Hearings Panel elected to delist the Company's common stock.

**2. Is the Company appealing the decision or pursuing reinstatement?**

Given the finality of the Panel's decision, we are now focused on forward-looking solutions — specifically, relisting our shares on perhaps another national exchange where we can provide the best liquidity and investor access. We are assessing all options.

**3. Where are Lipella's shares currently traded?**

As of June 19, 2025, Lipella's common stock is quoted on the OTC Pink Market<sup>1</sup> under the symbol **LIPO**. The Company remains a fully reporting public entity with continued SEC filings and investor disclosures. The Company's commitment to full and transparent filings in keeping with its past filing disciplines will not change.

**4. What steps is Lipella taking to relist on a national exchange?**

We are actively exploring relisting options on all national exchanges. We intend to submit an initial listing application as soon as possible and will provide stockholder updates as we progress and in conformity with such exchange's rules. Our management team is working with legal counsel and other trusted advisors to assess the most efficient path forward. We are committed to a relisting that aligns with our strategic goals and delivers long-term value to stockholders.

**5. How has the delisting impacted your clinical programs?**

Our clinical operations remain unaffected. We are continuing to execute on our core development programs, LP-10 for hemorrhagic cystitis and LP-310 for oral lichen planus, both of which address diseases with significant unmet medical need. The delisting has had no impact on our research, clinical staffing, or development timelines.

<sup>1</sup> Effective July 1, 2025, the OTC Pink market will be known as the OTCID.

**6. Can you provide a pipeline update?**

Yes. Lipella has two de-risked lead programs targeting underserved markets with significant commercial potential. LP-310, our lead clinical candidate, is in development for oral lichen planus (OLP), a chronic and painful inflammatory condition affecting the mucosal tissues of the mouth. There are currently no FDA-approved treatments and no known topical therapies in late-stage development for OLP. In May 2025, we presented statistically significant safety and efficacy data from the first two cohorts of our Phase 2a trial. These results showed strong clinical and patient-reported improvements in pain, ulceration, and disease severity, with no systemic exposure and a favorable safety profile.

Our second program, LP-10, is in development for hemorrhagic cystitis, another condition with limited therapeutic options. Both programs are supported by Lipella's in-house chemistry, manufacturing, and controls (CMC) capabilities, which provide us with supply chain flexibility and development speed.

**7. What are your upcoming clinical or regulatory milestones?**

We expect to report final topline data from the fully enrolled Phase 2a trial of LP-310 in the second half of 2025. The positive data presented to date support LP-310's potential as a first-in-class topical therapy for OLP. For LP-10, we are continuing development and preparing for additional regulatory interactions. Both programs are advancing on timelines consistent with our broader strategy and commercial readiness goals.

**8. What is your financial position and cash runway?**

Lipella remains operationally sound. We maintain prudent fiscal oversight and continue to fund our key priorities. Specific cash position details are disclosed in our most recent SEC filings, and we are capitalized to support current development programs.

**9. Did the delisting result from financial instability?**

No. The delisting was not related to financial distress or business performance. It stemmed from Nasdaq's conclusions based on its review of certain listing rules several months after the transactions closed and finding that placement agent compensation associated with those financings that was made in securities rather than cash did not fully conform to those rules' specifications. Lipella remains fundamentally strong, both operationally and clinically and the delisting did not impact that.

**10. Will you need to raise capital in the near term?**

As with all development-stage biotech companies, we continually evaluate our capital needs based on clinical progress. Any future financings will be structured strategically to minimize dilution and support a national exchange relisting.

**11. Will a reverse split be necessary?**

If required to meet price-based criteria for a national exchange or for other reasons that will be in our stockholders' best interests, a reverse stock split may be considered. We currently expect that such a step would only be undertaken in conjunction with a relisting plan that delivers meaningful benefits to stockholders.

**12. What considerations will go into pursuing one national exchange versus another?**

We will choose an exchange that provides the most viable path for clinical-stage biotech companies with strong fundamentals. We will look for a platform that is known for supporting early-stage innovation and provides robust liquidity and visibility. We will select an exchange that is well-aligned with our next phase of growth.

**13. What is your message to investors?**

While we are disappointed with Nasdaq's decision, Lipella's underlying business remains strong. We are advancing meaningful therapies through the clinical program previously outlined, maintaining full SEC compliance, and actively pursuing relisting. Our mission, leadership team, and long-term strategy remain unchanged.

**14. How are you communicating with stockholders during this transition?**

We will continue to issue regular press releases, file all required SEC disclosures, and engage investors directly. We are also evaluating investor conferences and calls to provide real-time updates and transparency.

**Sincerely,** 

**Jonathan Kaufman**

**CEO**

****

<br> **Forward-Looking Statements for Lipella Pharmaceuticals Inc.:**

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities, or future events or conditions, including, without limitation, those related to the anticipated developments of the Company's product candidates and the Company's plans to relist its common stock, which can be identified by terminology such as "may," "will," "expects," "anticipates," "aims," "potential," "future," "intends," "plans," "believes," "estimates," "continue," "likely to" and other similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are not historical facts and are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by its management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict, many of which are beyond the Company's control, including, without limitation, risks related to the Company's product candidates and ability to relist its common stock, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements. Any forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this communication, except as required by applicable law.

## Exhibit 99.2

**Exhibit 99.2** 

**Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting**

**PITTSBURGH, PA – June 25, 2025 –** *Lipella Pharmaceuticals Inc.* (OTC: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Executive Officer Jonathan Kaufman to stockholders. The letter provides detailed responses to frequently asked questions regarding the Company's recent delisting from the Nasdaq Capital Market, as well as insight into Lipella's clinical programs, financial position, and plans to relist on a national exchange.

In the letter, Dr. Kaufman acknowledged the many inquiries received from stockholders and reaffirmed the Company's commitment to transparency and long-term value creation.

"While we are disappointed with Nasdaq's decision, Lipella's underlying business remains strong. We are advancing meaningful therapies through the clinical program previously outlined, maintaining full SEC compliance, and actively pursuing relisting," said Dr. Kaufman. "Our mission, leadership team, and long-term strategy remain unchanged."

Key highlights from the letter include:

* **Relisting Plans**: The Company is actively evaluating national exchanges that support early-stage innovation and intends to file an initial listing
application in the near future.

* **Operational Continuity**: Lipella remains fully operational, with clinical programs advancing according to plan. The delisting has not impacted
clinical timelines or research staffing.

* **Clinical Pipeline Update**: The Company's lead candidates—LP-310 for oral lichen planus and LP-10 for hemorrhagic cystitis—continue
to show promising clinical progress. Final topline data from the Phase 2a trial of LP-310 is expected in the second half of 2025.

* **Financial Standing**: Lipella remains financially sound, with sufficient capital to support ongoing development programs and prudent fiscal management
in place.

* **Shareholder Engagement**: Lipella will continue to communicate through SEC filings, press releases, and investor outreach, including plans to participate
in investor conferences and calls.

The full stockholder letter is available in the Company's latest Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission today.

**About Lipella Pharmaceuticals Inc.**<br> Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at lipella.com and follow us on X and LinkedIn.

**Forward-Looking Statements**<br> This press release includes certain "forward-looking statements." All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, including our intention to pursue a relisting of our common stock on a national exchange, future operations, financial position, prospects, clinical trials, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, risks related to our product candidates, including LP-310 and LP-10, general capital market risks, including our ability to relist our common stock on a national exchange, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein.

**CONTACT:**<br> Jonathan Kaufman<br> Chief Executive Officer<br> Lipella Pharmaceuticals Inc.<br> Info@Lipella.com<br> 1-412-894-1853

**PCG Advisory**<br> Jeff Ramson<br> jramson@pcgadvisory.com